Literature DB >> 12819986

Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy.

Anke Rohde1, Joerg Dembinski, Christoph Dorn.   

Abstract

CASE REPORT: We present the case of a 25-year-old woman with treatment resistant hyperemesis gravidarum in the 15th week with a 13 kg loss of body weight. When the patient asked for termination of the pregnancy because of the unbearable symptoms, treatment with intravenous mirtazapine (Remergil) was started.
RESULTS: Nausea and vomiting disappeared within hours, pregnancy termination was no longer desired. The patient was discharged two weeks later in good health and at 36 weeks gestation a cesarean section was performed. Post partum evaluation as well as 6-month post-partum revealed no dysmorphology or laboratory abnormalities in the children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819986     DOI: 10.1007/s00404-003-0502-0

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  11 in total

Review 1.  Treatment options for hyperemesis gravidarum.

Authors:  Amy Abramowitz; Emily S Miller; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2017-01-09       Impact factor: 3.633

2.  [Mirtazapine and hyperemesis gravidarum].

Authors:  M Lieb; U Palm; D Jacoby; T C Baghai; E Severus
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

3.  Tricyclic antidepressants for chronic vomiting in diabetic patients.

Authors:  Mandeep S Sawhney; Chandra Prakash; Patrick J Lustman; Ray E Clouse
Journal:  Dig Dis Sci       Date:  2006-12-30       Impact factor: 3.199

4.  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.

Authors:  Jun Cao; Quchang Ouyang; Shusen Wang; Joseph Ragaz; Xiaojia Wang; Yuee Teng; Biyun Wang; Zhonghua Wang; Jian Zhang; Leiping Wang; Jiong Wu; Zhimin Shao; Xichun Hu
Journal:  Invest New Drugs       Date:  2020-02-08       Impact factor: 3.850

Review 5.  The safety of newer antidepressants in pregnancy and breastfeeding.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.

Authors:  Abdulkader Alam; Zoya Voronovich; Joseph A Carley
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-10

Review 7.  Pregnancy-associated liver disorders.

Authors:  Iryna S Hepburn; Robert R Schade
Journal:  Dig Dis Sci       Date:  2008-02-07       Impact factor: 3.199

Review 8.  Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

9.  Behavioral and developmental changes in rats with prenatal exposure of mirtazapine.

Authors:  Jasmita Sahoo; Ashok K Pattnaik; Nibha Mishra
Journal:  Sci Pharm       Date:  2010-06-30

10.  Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.

Authors:  Anne Ostenfeld; Tonny Studsgaard Petersen; Tina Bergmann Futtrup; Jon Trærup Andersen; Andreas Kryger Jensen; Hanne Brix Westergaard; Lars Henning Pedersen; Ellen Christine Leth Løkkegaard
Journal:  BMJ Open       Date:  2020-03-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.